Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME(TM)) in healthy volunteers

Journal of Clinical Pharmacology

Volumn 40, Issue 12 II, 2000, Pages 1462-1469

  Sandberg, J A ^a   Parker, V P ^a   Blanchard, K S ^a   Sweedler, D ^a   Powell, J A ^a   Kachensky, A ^a   Bellon, L ^a   Usman, N ^a   Rossing, T ^a   Borden, E ^a   Blatt, L M ^a  

^a Sirna Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOZYME; RIBOZYME;

ADULT; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MALE; RHINITIS; SOMNOLENCE;

ADULT; ANGIOGENESIS INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; RNA, CATALYTIC;

EID: 0033750282     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. VEGF-mediated tumour angiogenesis: A new target for cancer therapy
2. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis
3. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF
4. Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies
5. Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis
6. Regulation of the expression of the VEGF/VPS and its receptors: Role in tumor angiogenesis
7. Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: The key to angiogenesis?
8. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract
9. Design, synthesis, and function of therapeutic hammerhead ribozymes
10. Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint
11. Optimizing the cell efficacy of synthetic ribozymes: Site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb
12. A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo
13. Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA
14. Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens
15. Antitumor and antimetastatic activity of ribozymes targeting the mRNA of vascular growth factor receptors
16. Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME(TM)) targeting VEGF receptor mRNA in the cynomolgus monkey
17. Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse
18. Synthesis, deprotection, analysis and purification of RNA and ribozymes
19. Chemical modification of hammerhead ribozymes: Catalytic activity and nuclease resistance
20. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action
21. Inhibition of coagulation by a phosphorothioate oligonucleotide
22. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302)
23. Pharmacokinetics and tolerability of intravenous Trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects
24. Repeat-dose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys
25. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects
26. Purification and properties of ribonucleases from human urine